Perjeta(pertuzumab)
Perjeta, Phesgo (pertuzumab) is an antibody pharmaceutical. Pertuzumab was first approved as Perjeta on 2012-06-08. It is used to treat breast neoplasms in the USA. It has been approved in Europe to treat breast neoplasms. The pharmaceutical is active against receptor tyrosine-protein kinase erbB-2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Perjeta
CombinationsPhesgo
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
pertuzumab, Perjeta, Genentech, Inc. | |||
| 2024-06-08 | Reference product excl. | ||
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01F: Monoclonal antibodies and antibody drug conjugates
— L01FD: Her2 (human epidermal growth factor receptor 2) inhibitors
— L01FD02: Pertuzumab
— L01X: Other antineoplastic agents in atc
— L01XY: Combinations of antineoplastic agents
— L01XY02: Pertuzumab and trastuzumab
Clinical
Clinical Trials
379 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 48 | 148 | 63 | 9 | 44 | 287 |
| Male breast neoplasms | D018567 | — | — | 3 | 5 | — | 1 | 1 | 9 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 12 | 20 | 3 | — | 3 | 32 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 6 | 9 | 3 | — | 4 | 18 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | 5 | 2 | — | — | 8 |
| Prostatic neoplasms | D011471 | — | C61 | 2 | 5 | 1 | — | — | 7 |
| Adenocarcinoma | D000230 | — | — | 1 | 5 | 2 | — | — | 7 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 2 | 5 | 2 | — | — | 7 |
| Inflammatory breast neoplasms | D058922 | — | — | 1 | 4 | 3 | — | — | 7 |
| Colorectal neoplasms | D015179 | — | — | — | 5 | 1 | — | 1 | 6 |
| Hematologic neoplasms | D019337 | — | — | 1 | 4 | 2 | — | — | 5 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 3 | 1 | — | — | 5 |
Show 19 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Triple negative breast neoplasms | D064726 | — | — | 1 | 6 | — | — | — | 7 |
| Non-small-cell lung carcinoma | D002289 | — | — | 2 | 5 | — | — | — | 6 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 3 | 4 | — | — | — | 5 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | 3 | — | — | — | 4 |
| Rectal neoplasms | D012004 | — | — | 1 | 4 | — | — | — | 4 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | 2 | — | — | — | 3 |
| Gastrointestinal neoplasms | D005770 | — | C26.9 | 2 | 2 | — | — | — | 3 |
| Biliary tract neoplasms | D001661 | — | C24.9 | 1 | 3 | — | — | — | 3 |
| Invasive hydatidiform mole | D002820 | — | D39.2 | 1 | 3 | — | — | — | 3 |
| Neoadjuvant therapy | D020360 | — | — | — | 3 | — | — | — | 3 |
Show 39 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | 1 | 3 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 1 | — | — | — | — | 1 |
| Primary myelofibrosis | D055728 | — | D47.4 | 1 | — | — | — | — | 1 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | — | — | — | — | 1 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 1 | — | — | — | — | 1 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | — | — | — | — | 1 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 1 | — | — | — | — | 1 |
| Anemia | D000740 | EFO_0004272 | D64.9 | 1 | — | — | — | — | 1 |
Show 12 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiotoxicity | D066126 | EFO_1001482 | — | — | — | — | — | 2 | 2 |
| Vomiting | D014839 | — | R11.1 | — | — | — | — | 1 | 1 |
| Cardiac rehabilitation | D000072038 | — | — | — | — | — | — | 1 | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 1 | 1 |
| Molecular targeted therapy | D058990 | — | — | — | — | — | — | 1 | 1 |
| Feasibility studies | D005240 | — | — | — | — | — | — | 1 | 1 |
| Contraceptive effectiveness | D000073516 | — | — | — | — | — | — | 1 | 1 |
| Residual neoplasm | D018365 | — | — | — | — | — | — | 1 | 1 |
| Peripheral nervous system diseases | D010523 | — | G64 | — | — | — | — | 1 | 1 |
| Sarcopenia | D055948 | EFO_1000653 | M62.84 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Pertuzumab |
| INN | pertuzumab |
| Description | Pertuzumab (humanized mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >4LLY:A,C|mutated Pertuzumab Fab heavy chain
EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRKAPGKGLEWVADVNPNSGGSIYNQEFKGRFTLSVDRSKNTLY
LQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSW
NSGALTSGVATGPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH
>4LLY:B,D|light chain Clambda
RIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQDKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQP
EDFATYYCQQYYIYPYTFGQGTKVEIKGQPKAAPSVTLFPPSSEELQANKATLVCYISDFYPGAVTVAWKADSSPVKAGV
ETTTPSKQSNNKYAAWSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTEC |
Identifiers
| PDB | 1S78, 4LLU, 4LLW, 4LLY, 5VSH, 6OGE |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2007641 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB06366 |
| UNII ID | K16AIQ8CTM (ChemIDplus, GSRS) |
Target
Agency Approved
ERBB2
ERBB2
Organism
Homo sapiens
Gene name
ERBB2
Gene synonyms
HER2, MLN19, NEU, NGL
NCBI Gene ID
Protein name
receptor tyrosine-protein kinase erbB-2
Protein synonyms
c-erb B2/neu protein, CD340, herstatin, human epidermal growth factor receptor 2, Metastatic lymph node gene 19 protein, MLN 19, neuro/glioblastoma derived oncogene homolog, neuroblastoma/glioblastoma derived oncogene homolog, p185erbB2, Proto-oncogene c-ErbB-2, Proto-oncogene Neu, Tyrosine kinase-type cell surface receptor HER2, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2, v-erb-b2 avian erythroblastic leukemia viral oncoprotein 2, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog
Uniprot ID
Mouse ortholog
Erbb2 (13866)
receptor tyrosine-protein kinase erbB-2 (Q6ZPE0)
Alternate
No data
Variants
No data
Financial
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 13,069 documents
View more details
Safety
Black-box Warning
Black-box warning for: Perjeta, Phesgo
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
27,023 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use